CF
BCLI

Centaurus Financial’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Centaurus Financial’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-27
Closed -$2K – 669
2018
Q2 		$2K Buy
+27
New +$1.59K ﹤0.01% 1986

Other funds holding BCLI

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PVH
Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
CPP
Crow Point Partners Boston, Massachusetts $64M AUM 33.5% 1-Year Est. Return

Centaurus Financial's BCLI Position: Q3 2018 in Review

Centaurus Financial sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2018, closing a stake of 27 shares — an estimated $2K sold.

Centaurus Financial first reported a position in BCLI in Q2 2018 and held it in 1 quarter. The position peaked at $2K in Q2 2018. 37 funds tracked by Wall St. Rank hold BCLI as of Q3 2018.

  • Centaurus Financial reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2018 after selling out during the quarter.
  • Centaurus Financial sold 27 BRAINSTORM CELL THERAPUTC shares in Q3 2018, an estimated $2K.
  • Centaurus Financial first reported a position in BRAINSTORM CELL THERAPUTC in Q2 2018 and held it in 1 quarter.
  • Centaurus Financial's BRAINSTORM CELL THERAPUTC position peaked at $2K in Q2 2018.
  • 37 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2018.

Based on Centaurus Financial's 13F filing for Q3 2018, filed 5 Nov 2018.